VEGFA and hemorrhage: Anti-VEGF therapy, a cornerstone in managing neovascular AMD and associated hemorrhages, appears to demonstrate consistently favorable cost–utility metrics, reflecting its established efficacy in stabilizing or improving visual outcomes with relatively low associated costs.